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Purpose
Mucuna pruriens (mucuna) seeds contain 3-6% L-
DOPA, and have been used in traditional Ayurvedic
medicine to treat diseases resembling Parkinson’sd i s -
ease (PD). Pilot studies in PD show that mucuna seed
powder has similar effects to conventional levodopa/car-
bidopa medication. Formulations of mucuna seed are
readily available through the internet, and are used by
some PD patients as an alternative to conventional leva-
dopa/carbidopa medication. The purpose of this study
was to examine the L-DOPA content of a range of pop-
ular mucuna products in order to assess the veracity of
label claims.
Methods
Six different brands of mucuna product were ordered
through the internet. Certificates of analysis were
obtained where possible. A standard amount of each
product was extracted using methanol: formic acid for
analysis using reversed-phase high performance liquid
chromatography (HPLC) with ultraviolet and fluores-
cence detection. L-DOPA content was calculated using
a standard curve prepared using L-DOPA (Sigma-
Aldrich) as reference.
Results
The claimed L-DOPA content ranged from 25 to 250mg
per dose for the six products. HPLC analysis revealed
that only two of the products had L-DOPA values close
to the value claimed. The remaining products contained
considerably less L-DOPA , <10% in two cases, than
implied on the label. Certificates of analysis suggested
that not all manufacturers routinely measure L-DOPA
content of their mucuna product.
Conclusion
Four of six products examined showed a large discre-
pancy between label claim and L-DOPA content, inde-
pendently measured by HPLC. This finding warrants
further investigation as these deficiencies could impact
both patients, and the outcome of clinical studies using
these products.
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